GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Additional Paid-In Capital

Lirum Therapeutics (Lirum Therapeutics) Additional Paid-In Capital : $6.50 Mil(As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Additional Paid-In Capital?


Lirum Therapeutics's quarterly additional paid-in capital increased from Dec. 2022 ($0.00 Mil) to Sep. 2023 ($6.60 Mil) but then stayed the same from Sep. 2023 ($6.60 Mil) to Dec. 2023 ($6.50 Mil).

Lirum Therapeutics's annual additional paid-in capital stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($6.50 Mil).

Lirum Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Lirum Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Additional Paid-In Capital Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
- - 6.50

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Additional Paid-In Capital - - - 6.60 6.50

Lirum Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Lirum Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Website
https://www.lirumtx.com
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines